Evidence map›Paper›PMID 28589231›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2017

A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease.

Atsushi Funatsu, Shigeru Nakamura, Naoto Inoue, Shinsuke Nanto, Masato Nakamura, Masashi Iwabuchi, Kenji Ando, Ryuta Asano, Seiji Habara, Shigeru Saito and 2 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Clinical outcomes of percutaneous coronary intervention forFrontiers in cardiovascular medicine · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Drug-Coated Balloons Beyond In-Stent Restenosis.Reviews in cardiovascular medicine · 2026
    Review
  12. Review
  13. Observational
  14. Article
  15. Three-Year Outcome of Drug Coated Balloon Angioplasty Following Atherectomy for Severely Calcified Coronary Lesions.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Atsushi FunatsuKyoto Katsura Hospital, Kyoto, Japan. kcvc.funatsu@katsura.com.
Shigeru NakamuraKyoto Katsura Hospital, Kyoto, Japan.
Naoto InoueSendai Kousei Hospital, Sendai, Japan.
Shinsuke NantoOsaka University Graduate school of Medicine, Osaka, Japan.
Masato NakamuraToho University Ohashi Medical Center, Tokyo, Japan.
Masashi IwabuchiKokura Memorial Hospital, Kitakyushu, Japan.
Kenji AndoKokura Memorial Hospital, Kitakyushu, Japan.
Ryuta AsanoSakakibara Heart institute, Tokyo, Japan.
Seiji HabaraKurashiki Central Hospital, Kurashiki, Japan.
Shigeru SaitoShonan Kamakura General Hospital, Kamakura, Japan.
Ken KozumaTeikyo University Hospital, Tokyo, Japan.
Kazuaki MitsudoKurashiki Central Hospital, Kurashiki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe investigated the efficacy and safety of using paclitaxel-coated balloon (PCB) to treat small vessel disease. METHODS AND

resultsIn this multicenter, prospective, randomized controlled trial, one-hundred and thirty-five patients with native coronary lesions in small vessels were randomized into a PCB group and plain balloon angioplasty (POBA) group at a ratio of 2:1. There were no differences in target vessel failure (TVF) that was defined as cardiac death or target vessel-related myocardial infarction or target lesion revascularization (TLR), between the two groups (3.4 vs. 10.3%; P = 0.20), and TLR was slightly lower in the PCB group (2.3%) than that in the POBA group (10.3%) during 24 weeks follow-up. The late lumen loss (LLL) was significantly lower in the PCB group (0.01 ± 0.31 vs. 0.32 ± 0.34 mm; P < 0.01) and late lumen enlargement (LLE) was more frequently observed in the PCB group (48 vs. 15%; P < 0.01) by angiographic follow-up after 24 weeks. There were no cases of death, myocardial infarction, thrombosis and reocclusion in either group.

conclusionsThis study was not able to demonstrate superiority of PCB compared with POBA.

Indexed as

Drug-Eluting StentsAgedAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary VesselsFemaleFollow-Up StudiesHumansMalePaclitaxelProspective StudiesProsthesis DesignTime FactorsTreatment OutcomePaclitaxelTubulin ModulatorsBalloon angioplastyNative coronary arteryPaclitaxel-coated balloonSmall vessel disease

Identifiers

PMID28589231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.